Intrinsiqq
Nuformix Plc logo

Nuformix Plc Quality Score

NFX.XLON

Compare
Quality10

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-1.7x

Negative earnings, no valuation support

Cash Flow Multiple
0/100
-1.8x

Negative FCF, no valuation support

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
0/100
186.1%

Heavy dilution above 5%

Capital Structure
100/100
-£97550

Net cash position, no leverage concern

2021
£2.00M
£0.00
2022
£464095
£0.00
2024
£20210
£0.00
2025
£97550
£0.00
TTM
£97550
£0.00
CashDebt
Return on Capital
0/100
-71.0%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Nuformix (NFX.XLON) quality: score, margins and returns

Nuformix (NFX.XLON) scores 10/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 4 metrics each scored 0 to 100 and -71.0% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is Nuformix (NFX.XLON) a high-quality business?+

Nuformix scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -71.0% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Nuformix's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from NFX.XLON's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Nuformix scores well and where it falls behind.

What is Nuformix's return on invested capital (ROIC)?+

Nuformix earns about -71.0% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to NFX.XLON's margins and growth on this scorecard to judge durability.

How the market compares: US profitability statistics

Peers

Biotechnology · Pick stocks to compare with NFX.XLON

CompareIntrinsic value
EVG.XLONEvgen Pharma PLC
£0.00-2.42%40
AZN.XLONAstraZeneca PLC
£134.12+0.81%56
SPI.XLONSpire Healthcare Group plc
£2.49+0.61%63
ROQ.XLONRoquefort Therapeutics plc
£0.06-1.33%10
OXB.XLONOxford Biomedica plc
£4.89-4.68%26
ONT.XLONOxford Nanopore Technologies plc
£1.88-5.91%18
HEMO.XLONHemogenyx Pharmaceuticals Plc
£6.21-10.07%0
GNS.XLONGenus plc
£20.76-2.35%62

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing NFX.XLON

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.